Conjugate vaccines are among the most effective methods for preventing bacterial infections, representing a promising strategy to combat drug-resistant pathogens. However, existing manufacturing approaches limit access to conjugate vaccines due to centralized production and cold chain distribution requirements. To address these limitations, we developed a modular technology for in vitro bioconjugate vaccine expression (iVAX) in portable, freeze-dried lysates from detoxified, nonpathogenic Escherichia coli. Upon rehydration, iVAX reactions synthesize clinically relevant doses of bioconjugate vaccines against diverse bacterial pathogens in one hour.
Introduction
Drug-resistant bacteria are predicted to threaten up to 10 million lives per year by 2050 (The Review on Antimicrobial Resistance, 2014), necessitating new strategies to develop and distribute antibiotics and vaccines. Conjugate vaccines, typically composed of a pathogen-specific capsular (CPS) or O-antigen polysaccharide (O-PS) linked to an immunostimulatory protein carrier, are among the safest and most effective methods for preventing life-threatening bacterial infections (Jin et al., 2017; Trotter et al., 2008; Weintraub, 2003) . In particular, implementation of meningococcal and pneumococcal conjugate vaccines have significantly reduced the occurrence of bacterial meningitis and pneumonia worldwide (Novak et al., 2012; Poehling et al., 2006) , in addition to reducing antibiotic resistance in targeted strains (Roush et al., 2008) . However, despite their proven safety and efficacy, global childhood vaccination rates for conjugate vaccines remain as low as ~30%, with lack of access or low immunization coverage accounting for the vast majority of remaining disease burden (Wahl et al., 2018) . In addition, the 2018 WHO prequalification of Typhbar-TCV ® to prevent typhoid fever represents the first conjugate vaccine approval in nearly a decade. In order to address emerging drug-resistant pathogens, new technologies to accelerate the development and global distribution of conjugate vaccines are needed.
Contributing to the slow pace of conjugate vaccine development and distribution is the fact that these molecules are particularly challenging and costly to manufacture. The conventional process to produce conjugate vaccines involves chemical conjugation of carrier proteins with polysaccharide antigens purified from large-scale cultures of pathogenic bacteria. Large-scale fermentation of pathogens results in high manufacturing costs due to associated biosafety hazards and process development challenges. In addition, chemical conjugation can alter the structure of the polysaccharide, resulting in loss of the protective epitope (Bhushan et al., 1998) .
To address these challenges, it was recently demonstrated that polysaccharide-protein "bioconjugates" can be made in Escherichia coli using protein-glycan coupling technology (PGCT) (Feldman et al., 2005) . In this approach, engineered E. coli cells covalently attach heterologously expressed CPS or O-PS antigens to carrier proteins via an asparagine-linked glycosylation reaction catalyzed by the Campylobacter jejuni oligosaccharyltransferase enzyme PglB (CjPglB) (Cuccui et al., 2013; Garcia-Quintanilla et al., 2014; Ihssen et al., 2010; Ma et al., 2014; Marshall et al., 2018; Wacker et al., 2014; Wetter et al., 2013) . Despite this advance, both chemical conjugation and PGCT approaches rely on living bacterial cells, requiring centralized production facilities from which vaccines are distributed via a refrigerated supply chain. Refrigeration is critical to avoid conjugate vaccine spoilage due to precipitation and significant loss of the pathogen-specific polysaccharide upon both heating and freezing (Frasch, 2009; WHO, 2014) .
Only one conjugate vaccine, MenAfriVac TM , is known to remain active outside of the cold chain for up to 4 days, which enabled increased vaccine coverage and an estimated 50% reduction in costs during vaccination in the meningitis belt of sub-Saharan Africa (Lydon et al., 2014) .
However, this required significant investment in the development and validation of a thermostable vaccine. Broadly, the need for cold chain refrigeration creates economic and logistical challenges that limit the reach of vaccination campaigns and present barriers to the eradication of disease, especially in the developing world (Ashok et al., 2017; Wahl et al., 2018) .
Cell-free protein synthesis (CFPS) offers opportunities to both accelerate vaccine development and enable decentralized, cold chain-independent biomanufacturing by using cell lysates, rather than living cells, to synthesize proteins in vitro (Carlson et al., 2012) . Importantly, CFPS platforms (i) enable point-of-care protein production, as relevant amounts of protein can be synthesized in vitro in just a few hours, (ii) can be freeze-dried for distribution at ambient temperature and reconstituted by just adding water (Adiga et al., 2018; Pardee et al., 2016) , and (iii) circumvent biosafety concerns associated with the use of living cells outside of a controlled laboratory setting. CFPS has recently been used to enable on-demand and portable production of aglycosylated protein vaccines (Adiga et al., 2018; Pardee et al., 2016) . Moreover, we recently described a cell-free glycoprotein synthesis technology that enables one-pot production of glycosylated proteins, including human glycoproteins and eukaryotic glycans (Jaroentomeechai et al., 2018) . Despite these advances, cell-free systems and even decentralized manufacturing systems have historically been limited by their inability to synthesize glycosylated proteins at relevant titers and bearing diverse glycan structures, such as the polysaccharide antigens needed for bioconjugate vaccine production .
To address these limitations, here we describe the iVAX (in vitro bioconjugate vaccine expression) platform that enables rapid development and cold chain-independent biosynthesis of conjugate vaccines in cell-free reactions (Figure 1) . iVAX was designed to have the following features. First, iVAX is fast, with the ability to produce multiple individual doses of bioconjugates in one hour. Second, iVAX is robust, yielding equivalent amounts of bioconjugate over a range of operating temperatures. Third, iVAX is modular, offering the ability to rapidly interchange carrier proteins, including those used in licensed conjugate vaccines, as well as conjugated polysaccharide antigens. We leverage this modularity to create an array of vaccine candidates targeted against diverse bacterial pathogens, including the highly virulent Franciscella tularensis subsp. tularensis (type A) strain Schu S4, enterotoxigenic (ETEC) E. coli O78, and uropathogenic (UPEC) E. coli O7. Fourth, iVAX is shelf-stable, derived from freeze-dried cell-free reactions that operate in a just-add-water strategy. Fifth, iVAX is safe, leveraging lipid A remodeling that effectively avoids the high levels of endotoxin present in non-engineered E. coli manufacturing platforms. Our results demonstrate that anti-F. tularensis bioconjugates derived from freeze-dried, low-endotoxin iVAX reactions elicit pathogen-specific antibody responses in mice and outperform a bioconjugate produced using the established PGCT approach in living cells. Overall, the iVAX platform offers a new way to deliver the protective benefits of an important class of antibacterial vaccines to both the developed and developing world.
Figure 1. iVAX platform enables on-demand and portable production of antibacterial vaccines.
The in vitro bioconjugate vaccine expression (iVAX) platform provides a rapid means to develop and distribute vaccines against bacterial pathogens. Expression of pathogen-specific polysaccharides (e.g., CPS, O-PS) and a bacterial oligosaccharyltransferase enzyme in engineered nonpathogenic E. coli with detoxified lipid A yields low-endotoxin lysates containing all of the machinery required for synthesis of bioconjugate vaccines. Reactions catalyzed by iVAX lysates can be used to produce bioconjugates containing licensed carrier proteins and can be freeze-dried without loss of activity for refrigeration-free transportation and storage. Freeze-dried reactions can be activated at the point-of-care via simple rehydration and used to reproducibly synthesize immunologically active bioconjugates in ~1 h.
Results
In vitro synthesis of licensed vaccine carrier proteins. To demonstrate proof-of-principle for cell-free bioconjugate vaccine production, we first set out to express a set of carrier proteins that are currently used in FDA-approved conjugate vaccines. Producing these carrier proteins in soluble conformations in vitro represented an important benchmark because their expression in living E. coli has proven challenging, often requiring purification and refolding of insoluble product from inclusion bodies (Haghi et al., 2011; Stefan et al., 2011) , fusion of expression partners such as maltose-binding protein (MBP) to increase soluble expression (Figueiredo et al., 1995; Stefan et al., 2011) , or expression of truncated protein variants in favor of the full-length proteins (Figueiredo et al., 1995) . In contrast, cell-free protein synthesis approaches have recently shown
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On-demand vaccine synthesis at the point-of-care promise for difficult-to-express proteins . The carrier proteins that we focused on here included nonacylated H. influenzae protein D (PD), the N. meningitidis porin protein (PorA), and genetically detoxified variants of the Corynebacterium diphtheriae toxin (CRM197) and the Clostridium tetani toxin (TT). We also tested expression of the fragment C (TTc) and light chain (TTlight) domains of TT as well as E. coli MBP. While MBP is not a licensed carrier, it has demonstrated immunostimulatory properties (Fernandez et al., 2007) and when linked to O-PS was found to elicit polysaccharide-specific humoral and cellular immune responses in mice (Ma et al., 2014) . Similarly, the TT domains, TTlight and TTc, have not been used in licensed vaccines, but are immunostimulatory and individually sufficient for protection against C. tetani challenge in mice (Figueiredo et al., 1995) . To enable glycosylation, all carriers were modified at their C-termini with 4 tandem repeats of an optimal bacterial glycosylation motif, DQNAT (Chen et al., 2007) . A C-terminal 6xHis tag was also included to enable purification and detection via Western blot analysis. A variant of superfolder green fluorescent protein that contained an internal DQNAT glycosylation site (sfGFP 217-DQNAT ) (Jaroentomeechai et al., 2018) was used as a model protein to facilitate system development.
All eight carriers were synthesized in vitro with soluble yields of ~50-650 µg mL -1 as determined by 14 C-leucine incorporation (Figure 2a) . In particular, the MBP 4xDQNAT and PD 4xDQNAT variants were nearly 100% soluble, with yields of 500 µg mL -1 and 200 µg mL -1 , respectively, and expressed as exclusively full-length products according to Western blot analysis (Figure 2b) .
Notably, similar soluble yields were observed for all carriers at 25°C, 30°C, and 37°C, with the exception of CRM197 4xDQNAT (Figure S1a) , which is known to be heat sensitive (WHO, 2014) .
These results suggest that our method of cell-free carrier biosynthesis is robust over a 13 o C range in temperature and could be used in settings where precise temperature control is not feasible.
The open reaction environment of our cell-free reactions enabled facile manipulation of the chemical and reaction environment to improve production of more complex carriers. For example, in the case of the membrane protein PorA 4xDQNAT , lipid nanodiscs were added to increase soluble expression ( Figure S1b) . Nanodiscs provide a cellular membrane mimic to cotranslationally stabilize hydrophobic regions of membrane proteins (Bayburt and Sligar, 2010) .
For expression of TT, which contains an intermolecular disulfide bond, expression was carried out for 2 hours in oxidizing conditions (Knapp et al., 2007) , which improved assembly of the heavy and light chains into full-length product and minimized protease degradation of full-length TT ( Figure S1c) . In vitro synthesized CRM197 4xDQNAT and TT 4xDQNAT were comparable in size to commercially available purified diphtheria toxin (DT) and TT protein standards and were reactive with α-DT and α-TT antibodies, respectively (Figure S1d, e ), indicating that both were produced in immunologically relevant conformations. This is notable as CRM197 and TT are FDA-approved vaccine antigens for diphtheria and tetanus, respectively, when they are administered without conjugated polysaccharides. Together, our results highlight the ability of CFPS to express licensed conjugate vaccine carrier proteins in soluble conformations over a range of temperatures. Figure S1 .
On-demand synthesis of bioconjugate vaccines. We next sought to synthesize polysaccharide-conjugated versions of these carrier proteins by merging their in vitro expression with one-pot, cell-free glycosylation. As a model vaccine target, we focused on the highly virulent Francisella tularensis subsp. tularensis (type A) strain Schu S4, a gram-negative, facultative coccobacillus and the causative agent of tularemia. This bacterium is categorized as a class A bioterrorism agent due to its high fatality rate, low dose of infection, and ability to be aerosolized (Oyston et al., 2004) . Although there are currently no licensed vaccines against F. tularensis, several studies have independently confirmed the important role of antibodies directed against F. tularensis LPS, specifically the O-PS repeat unit, in providing protection against the Schu S4 strain (Fulop et al., 2001; Lu et al., 2012) . More recently, a bioconjugate vaccine comprising the F. tularensis Schu S4 O-PS (FtO-PS) conjugated to the Pseudomonas aeruginosa exotoxin A (EPA DNNNS-DQNRT ) carrier protein produced using PGCT (Cuccui et al., 2013; Marshall et al., 2018) was shown to be protective against challenge with the Schu S4 strain in a rat inhalation model of tularemia (Marshall et al., 2018) . In light of these earlier findings, we investigated the ability of the iVAX platform to produce anti-F. tularensis bioconjugate vaccine candidates on-demand by conjugating the FtO-PS structure to diverse carrier proteins in vitro.
The FtO-PS is composed of the 826-Da repeating tetrasaccharide unit Qui4NFm-(GalNAcAN)2-QuiNAc (Qui4NFm: 4,6-dideoxy-4-formamido-D-glucose; GalNAcAN: 2-acetamido-2-deoxy-D-galacturonamide; QuiNAc: 2-acetamido-2,6-dideoxy-D-glucose) (Prior et al., 2003) .
To glycosylate proteins with FtO-PS, we produced an iVAX lysate from glycoengineered E. coli cells expressing the FtO-PS biosynthetic pathway and the oligosaccharyltransferase enzyme CjPglB (Figure 3a) . This lysate, which contained lipid-linked FtO-PS and active CjPglB, was used to catalyze iVAX reactions primed with plasmid DNA encoding sfGFP 217-DQNAT . Control reactions in which attachment of the FtO-PS was not expected were performed with lysates from cells that lacked either the FtO-PS pathway or the CjPglB enzyme. We also tested reactions that lacked plasmid encoding the target protein sfGFP 217-DQNAT or were primed with plasmid encoding sfGFP 217-AQNAT , which contained a mutated glycosylation site (AQNAT) that is not modified by
CjPglB (Kowarik et al., 2006) . In reactions containing the iVAX lysate and primed with plasmid encoding sfGFP 217-DQNAT , immunoblotting with anti-His antibody or a commercial monoclonal antibody specific to FtO-PS revealed a ladder-like banding pattern (Figure 3b ). This ladder is characteristic of FtO-PS attachment, resulting from O-PS chain length variability through the action of the Wzy polymerase (Cuccui et al., 2013; Feldman et al., 2005; Prior et al., 2003) .
Glycosylation of sfGFP 217-DQNAT was observed only in reactions containing a complete glycosylation pathway and the preferred DQNAT glycosylation sequence (Figure 3b ). This Figure  S2 .
Next, we investigated whether FDA-approved carriers could be similarly conjugated with (Figure 4) . We observed conjugation of high molecular weight FtO-PS species (on the order of ~10-20 kDa) to all protein carriers tested, which is important as longer glycan chain length has been shown to increase the efficacy of conjugate vaccines against F.
tularensis (Stefanetti et al., 2019) . Notably, our attempts to synthesize the same panel of bioconjugates using the established PGCT approach in living E. coli yielded less promising results. Specifically, we observed low levels of FtO-PS glycosylation and lower molecular weight conjugated FtO-PS species for all PGCT-derived bioconjugates compared to their iVAX-derived counterparts ( Figure S3 ). The same trend was observed for PGCT-versus iVAX-derived bioconjugates involving the most common PGCT carrier protein, EPA DNNNS-DQNRT (Cuccui et al., 2013; Ihssen et al., 2010; Marshall et al., 2018; Wacker et al., 2014; Wetter et al., 2013) (Figure   4 ; Figure S3 ). In addition, only limited expression of the PorA membrane protein was achieved in vivo ( Figure S3 ). Collectively, these data indicate that iVAX could provide advantages over PGCT for production of bioconjugate vaccine candidates with high molecular weight O-PS antigens conjugated efficiently to diverse and potentially membrane-bound carrier proteins. We next asked whether the yields of bioconjugates produced using iVAX were sufficient to enable production of relevant vaccine doses. Recent clinical data show 1-10 μg doses of bioconjugate vaccine candidates are well-tolerated and effective in stimulating the production of antibacterial IgGs (Hatz et al., 2015; Huttner et al., 2017; Riddle et al., 2016) . To assess expression titers and for future experiments, we focused on MBP 4xDQNAT and PD 4xDQNAT because these carriers expressed in vitro with high soluble titers and without truncation products ( Figure   2 ). We found that reactions lasting ~1 hour produced ~20 μg mL −1 of glycosylated MBP 4xDQNAT and PD 4xDQNAT as determined by 14 C-leucine incorporation and densitometry analysis ( Figure   S4a ). It should be noted that vaccines are currently distributed in vials containing 1-20 doses of vaccine to minimize wastage (Humphreys, 2011) . Our yields suggest that multiple doses per mL can be synthesized in 1 hour using the iVAX platform.
To demonstrate the modularity of the iVAX approach for bioconjugate production, we sought to produce bioconjugates bearing O-PS antigens from additional pathogens including ETEC E. coli strain O78 and UPEC E. coli strain O7. E. coli O78 is a major cause of diarrheal disease in developing countries, especially among children, and a leading cause of traveler's diarrhea (Qadri et al., 2005) , while the O7 strain is a common cause of urinary tract infections (Johnson, 1991) . Like the FtO-PS, the biosynthetic pathways for EcO78-PS and EcO7-PS have been described previously and confirmed to produce O-PS antigens with the repeating units GlcNAc2Man2 (Jansson et al., 1987) and Qui4NAcMan(Rha)GalGlcNAc (L'vov et al., 1984) (GlcNAc: N-acetylglucosamine; Man: mannose; Qui4NAc: 4-acetamido-4,6-dideoxy-Dglucopyranose; Rha: rhamnose; Gal: galactose), respectively. Using iVAX lysates from cells expressing CjPglB and either the EcO78-PS and EcO7-PS pathways in reactions that were primed with PD 4xDQNAT or sfGFP 217-DQNAT plasmids, we observed carrier glycosylation only when both lipid-linked O-PS and CjPglB were present in the reactions (Figure S4b, c) . Our results demonstrate modular production of bioconjugates against multiple bacterial pathogens, enabled by compatibility of multiple heterologous O-PS pathways with in vitro carrier protein synthesis and glycosylation.
Endotoxin editing and freeze-drying yield iVAX reactions that are safe and portable. A key challenge inherent in using any E. coli-based system for biopharmaceutical production is the presence of lipid A, or endotoxin, which is known to contaminate protein products and can cause lethal septic shock at high levels (Russell, 2006) . As a result, the amount of endotoxin in formulated biopharmaceuticals is regulated by the United States Pharmacopeia (USP), US Food and Drug Administration (FDA), and the European Medicines Agency (EMEA) (Brito and Singh, 2011) . Because our iVAX reactions rely on lipid-associated components, such as CjPglB and FtO-PS, standard detoxification approaches involving the removal of lipid A (Petsch and Anspach, 2000) could compromise the activity or concentration of our glycosylation components in addition to increasing cost and processing complexities.
To address this issue, we adapted a previously reported strategy to detoxify the lipid A molecule through strain engineering (Chen et al., 2016; Needham et al., 2013) . In particular, the deletion of the acyltransferase gene lpxM and the overexpression of the F. tularensis phosphatase LpxE in E. coli has been shown to result in the production of nearly homogenous pentaacylated, monophosphorylated lipid A with significantly reduced toxicity but retained activity as an adjuvant (Chen et al., 2016) . This pentaacylated, monophosphorylated lipid A was structurally identical to the primary component of monophosphoryl lipid A (MPL) from Salmonella minnesota R595, an approved adjuvant composed of a mixture of monophosphorylated lipids (Casella and Mitchell, 2008) . To generate detoxified lipid A structures in the context of iVAX, we produced lysates from a ∆lpxM derivative of CLM24 that co-expressed FtLpxE and the FtO-PS glycosylation pathway (Figure 5a) . Lysates derived from this strain exhibited significantly decreased levels of toxicity compared to wild type CLM24 lysates expressing CjPglB and FtO-PS (Figure 5b) as measured by human TLR4 activation in HEK-Blue hTLR4 reporter cells (Needham et al., 2013) . Importantly, the structural remodeling of lipid A did not affect the activity of the membrane-bound CjPglB and FtO-PS components in iVAX reactions (Figure S5a) . By engineering the chassis strain for lysate production, we produced iVAX lysates with endotoxin levels <1,000 EU mL -1 , within the range of reported values for commercial protein-based vaccine products (0.288-180,000 EU mL -1 ) (Brito and Singh, 2011) .
A major limitation of traditional conjugate vaccines is that they must be refrigerated (WHO, 2014) , making it difficult to distribute these vaccines to remote or resource-limited settings. The ability to freeze-dry iVAX reactions for ambient temperature storage and distribution could alleviate the logistical challenges associated with refrigerated supply chains that are required for existing vaccines. To investigate this possibility, detoxified iVAX lysates were used to produce FtO-PS bioconjugates in two different ways: either by running the reaction immediately after priming with plasmid encoding the sfGFP 217-DQNAT target protein or by running after the same reaction mixture was lyophilized and rehydrated (Figure 5c ). In both cases, conjugation of FtO-PS to sfGFP 217-DQNAT was observed when CjPglB was present, with modification levels that were nearly identical (Figure 5d ). We also showed that detoxified, freeze-dried iVAX reactions can be scaled to 5 mL for production of FtO-PS-conjugated MBP 4xDQNAT and PD 4xDQNAT in a manner that was reproducible from lot to lot and indistinguishable from production without freeze-drying ( Figure S5b, c) . The ability to lyophilize iVAX reactions and manufacture bioconjugates without specialized equipment highlights the potential for portable, on-demand vaccine production. Figure S5 .
In vitro synthesized bioconjugates elicit pathogen-specific antibodies in mice. To validate the efficacy of bioconjugates produced using the iVAX platform, we next evaluated the ability of iVAX-derived bioconjugates to elicit anti-FtLPS antibodies in mice (Figure 6a) . Importantly, we found that BALB/c mice receiving iVAX-derived FtO-PS-conjugated MBP 4xDQNAT or PD 4xDQNAT produced high titers of FtLPS-specific IgG antibodies, which were significantly elevated compared to the titers measured in the sera of control mice receiving PBS or aglycosylated versions of each carrier protein (Figure 6b, Figure S6) . Interestingly, the IgG titers measured in sera from mice receiving glycosylated MBP 4xDQNAT derived from PGCT were similar to the titers observed in the control groups (Figure 6b, Figure S6 ), in line with the markedly weaker glycosylation of this candidate relative to its iVAX-derived counterpart (Figure S3) . Notably, both MBP 4xDQNAT and PD 4xDQNAT bioconjugates produced using iVAX elicited similar levels of IgG production and neither resulted in any observable adverse events in mice, confirming the modularity and safety of the technology for production of bioconjugate vaccine candidates.
We further characterized IgG titers by analysis of IgG1 and IgG2a subtypes and found that both iVAX-derived FtO-PS-conjugated MBP 4xDQNAT and PD 4xDQNAT boosted production of IgG1 antibodies by >2 orders of magnitude relative to all control groups as well as to glycosylated MBP 4xDQNAT derived from PGCT (Figure 6c ). This analysis also revealed that both iVAX-derived bioconjugates elicited a strongly Th2-biased (IgG1 >> IgG2a) response, which is characteristic of most conjugate vaccines (Bogaert et al., 2004) . Taken together, these results provide evidence that the iVAX platform supplies vaccine candidates that are capable of eliciting strong, pathogenspecific humoral immune responses and recapitulate the Th2 bias that is characteristic of licensed conjugate vaccines. 
Discussion
In this work we have established iVAX, a cell-free platform for portable, on-demand production of bioconjugate vaccines. We show that iVAX reactions can be detoxified to ensure Figure 5 iVAX-derived bioconjugates eicit pathogen-specific antibodies in mice.
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!"" !""" !"""" !""""" (Figueiredo et al., 1995; Haghi et al., 2011; Stefan et al., 2011) .
Further expansion of the O-PS pathways used in iVAX should be possible given the commonly observed clustering of polysaccharide biosynthesis genes in the genomes of pathogenic bacteria (Raetz and Whitfield, 2002) . This feature could make iVAX an attractive option for rapid, de novo development of bioconjugate vaccine candidates in response to a disease outbreak or against emerging drug-resistant bacteria.
Second, iVAX reactions are inexpensive, costing ~$12 mL -1 (Table S1) with the ability to synthesize ~20 μg bioconjugate mL -1 in one hour (Figure S4a) . Assuming a dose size of 10 μg, our iVAX reactions can produce a vaccine dose for ~$6. For comparison, the CDC cost per dose for conjugate vaccines ranges from ~$9.50 for the H. influenzae vaccine ActHIB ® to ~$75 and ~$118 for the meningococcal vaccine Menactra ® and pneumococcal vaccine Prevnar 13 ® , respectively (CDC, 2019).
Third, and rather interestingly, we observed that iVAX-derived bioconjugates were significantly more effective at eliciting FtLPS-specific IgGs than a bioconjugate derived from living E. coli cells using PGCT (Figure 6) . One possible explanation for this increased effectiveness is the more extensive glycosylation that we observed for the in vitro expressed bioconjugates, with greater carbohydrate loading and decoration with higher molecular weight FtO-PS species compared to their PGCT-derived counterparts. The reduced presence of high molecular weight
O-PS species observed on bioconjugates produced using PGCT could be due to competition between the O-antigen polymerase Wzy and PglB in vivo. In contrast, our in vitro approach decouples O-PS synthesis, which occurs in vivo before lysate production, from glycosylation, which occurs in vitro as part of iVAX reactions. Our results are consistent with previous reports of PGCT-derived anti-F. tularensis bioconjugates which show that increasing the ratio of conjugated
FtO-PS to protein in bioconjugates yields enhanced protection against F. tularensis Schu S4 in a rat inhalation model of tularemia (Marshall et al., 2018) . In addition, a recent study showed that a conjugate vaccine made with a high molecular weight (80 kDa) FtO-PS coupled to TT conferred better protection against intranasal challenge with F. tularensis live vaccine strain compared to a conjugate made with a low molecular weight (25 kDa) polysaccharide (Stefanetti et al., 2019) .
These results as well as our own point to the fact that a deeper understanding of important immunogen design features such as glycan loading and chain length could enable the production of more effective conjugate vaccines in the future.
Importantly, by enabling portable production of bioconjugate vaccines, iVAX addresses a key gap in both cell-free and decentralized biomanufacturing technologies. Production of glycosylated products has not yet been demonstrated in cell-based decentralized biomanufacturing platforms (Crowell et al., 2018; Perez-Pinera et al., 2016) and existing cell-free platforms using E. coli lysates lack the ability to synthesize glycoproteins (Boles et al., 2017; Murphy et al., 2019; Pardee et al., 2016; Salehi et al., 2016) . While glycosylated human erythropoietin has been produced in a cell-free biomanufacturing platform based on freeze-dried Chinese hamster ovary cell lysates (Adiga et al., 2018) , this and the vast majority of other eukaryotic cell-free and cell-based systems rely on endogenous protein glycosylation machinery.
As a result, these expression platforms offer little control over the glycan structures produced or the underlying glycosylation reactions, and significant optimization is often required to achieve acceptable glycosylation profiles (Adiga et al., 2018) . In contrast, the iVAX platform is enabled by lysates derived from E. coli that lack endogenous protein glycosylation pathways, allowing for bottom-up engineering of desired glycosylation activity (Jaroentomeechai et al., 2018) . The ability to engineer desired glycosylation activity in iVAX uniquely enables the production of an important class of antibacterial vaccines at the point-of-care.
In summary, iVAX provides a new approach for rapid development and portable, ondemand biomanufacturing of bioconjugate vaccines. The iVAX platform alleviates cold chain requirements, which could enhance delivery of medicines to regions with limited infrastructure and minimize vaccine losses due to spoilage. In addition, the ability to rapidly produce vaccine candidates in vitro provides a unique means for rapidly responding to pathogen outbreaks and emergent threats. As a result, we believe that the iVAX platform, along with an emerging set of technologies with the ability to synthesize biomedicines on-demand (Adiga et al., 2018; Boles et al., 2017; Crowell et al., 2018; Murphy et al., 2019; Pardee et al., 2016; Perez-Pinera et al., 2016; Salehi et al., 2016) , has the potential to promote increased access to complex, life-saving drugs through decentralized production. All other authors declare no competing financial interests.
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Experimental Model and Subject Details
Bacteria E. coli strains were grown in Luria Bertani (LB), LB-Lennox, or 2xYTP media at 30-37°C in shaking incubators, as specified in the Method Details section below. E. coli NEB 5-alpha (NEB) was used for plasmid cloning and purification. E. coli CLM24 or CLM24 ∆lpxM strains were used for preparing cell-free lysates. E. coli CLM24 was used as the chassis for expressing bioconjugates in vivo using PGCT. CLM24 is a glyco-optimized derivative of W3110 that carries a deletion in the gene encoding the WaaL ligase, facilitating the accumulation of preassembled glycans on undecaprenyl diphosphate (Feldman et al., 2005) . CLM24 ∆lpxM has an endogenous acyltransferase deletion and serves as the chassis strain for production of detoxified cell-free lysates.
Human cell culture
HEK-Blue hTLR4 cells (Invivogen) were cultured in DMEM media high glucose/L-glutamine supplement with 10% fetal bovine serum, 50 U mL -1 penicillin, 50 mg mL -1 streptomycin, and 100 μg mL -1 Normacin TM in a humidified incubator at 37 o C with 5% CO2, per manufacturer's specifications.
Mice
Six-week old female BALB/c mice obtained from Harlan Sprague Dawley were randomly assigned to experimental groups. Mice were housed in groups of three to five animals and cages were changed weekly. All animals were observed daily for behavioral and physical health such as visible signs of injury and abnormal grooming habits. Mice were also observed 24 and 48 hours after each injection and no abnormal responses were reported. This study was performed at 
Method Details
Construction of CLM24 ∆lpxM strain E. coli CLM24 ∆lpxM was generated using the Datsenko-Wanner gene knockout method (Datsenko and Wanner, 2000) . Briefly, CLM24 cells were transformed with the pKD46 plasmid encoding the λ red system. Transformants were grown to an OD600 of 0.5-0.7 in 25 mL LB-Lennox media (10 g L -1 tryptone, 5 g L -1 yeast extract and 5 g L -1 NaCl) with 50 μg mL -1 carbenicillin at 30°C, harvested and washed three times with 25 mL ice-cold 10% glycerol to make them electrocompetent, and resuspended in a final volume of 100 μL 10% glycerol. In parallel, a lpxM knockout cassette was generated by PCR amplifying the kanamycin resistance cassette from pKD4 with forward and reverse primers with homology to lpxM. Electrocompetent cells were transformed with 400 ng of the lpxM knockout cassette and plated on LB agar with 30 μg mL -1 kanamycin for selection of resistant colonies. Plates were grown at 37°C to cure cells of the pKD46 plasmid. Colonies that grew on kanamycin were confirmed to have acquired the knockout cassette via colony PCR and DNA sequencing. These confirmed colonies were then transformed with pCP20 to remove the kanamycin resistance gene via Flp-FRT recombination. Transformants were plated on LB agar with 50 μg mL -1 carbenicillin. Following selection, colonies were grown in liquid culture at 42°C to cure cells of the pCP20 plasmid. Colonies were confirmed to have lost both lpxM and the knockout cassette via colony PCR and DNA sequencing and confirmed to have lost both kanamycin and carbenicillin resistance via replica plating on LB agar plates with 50 μg mL -1 carbenicillin or kanamycin. All primers used for construction and validation of this strain are listed in Table S2 .
All plasmids used in the study are listed in Table S3 . Plasmids pJL1-MBP 4xDQNAT , pJL1-PD 4xDQNAT , pJL1-PorA 4xDQNAT , pJL1-TTc 4xDQNAT , pJL1-TTlight 4xDQNAT , pJL1-CRM197 4xDQNAT , and pJL1-TT 4xDQNAT were generated via PCR amplification and subsequent Gibson Assembly of a codon optimized gene construct purchased from IDT with a C-terminal 4xDQNAT-6xHis tag (Fisher et al., 2011) between the NdeI and SalI restriction sites in the pJL1 vector. Plasmid pJL1-EPA DNNNS-DQNRT was constructed using the same approach, but without the addition of a C-terminal 4xDQNAT-6xHis tag. Plasmids pTrc99s-ssDsbA-MBP 4xDQNAT , pTrc99s-ssDsbA-PD 4xDQNAT , pTrc99s-ssDsbA-PorA 4xDQNAT , pTrc99s-ssDsbA-TTc 4xDQNAT , pTrc99s-ssDsbA-TTlight 4xDQNAT , and pTrc99s-ssDsbA-EPA DNNNS-DQNRT were created via PCR amplification of each carrier protein gene and insertion into the pTrc99s vector between the NcoI and HindIII restriction sites via Gibson
Assembly. Plasmid pSF-CjPglB-LpxE was constructed using a similar approach, but via insertion of the lpxE gene from pE (Needham et al., 2013) between the NdeI and NsiI restriction sites in the pSF vector. Inserts were amplified via PCR using Phusion® High-Fidelity DNA polymerase (NEB) with forward and reverse primers designed using the NEBuilder® Assembly Tool (nebuilder.neb.com) and purchased from IDT. The pJL1 vector (Addgene 69496) was digested using restriction enzymes NdeI and SalI-HF® (NEB). The pSF vector was digested using restriction enzymes NdeI and NotI (NEB). PCR products were gel extracted using an EZNA Gel Extraction Kit (Omega Bio-Tek), mixed with Gibson assembly reagents and incubated at 50°C for 1 hour. Plasmid DNA from the Gibson assembly reactions were transformed into E. coli NEB 5alpha cells and circularized constructs were selected using kanamycin at 50 μg ml -1 (Sigma).
Sequence-verified clones were purified using an EZNA Plasmid Midi Kit (Omega Bio-Tek) for use in CFPS and iVAX reactions.
Cell-free lysate preparation E. coli CLM24 source strains were grown in 2xYTP media (10 g/L yeast extract, 16 g/L tryptone, 5 g/L NaCl, 7 g/L K2HPO4, 3 g/L KH2PO4, pH 7.2) in shake flasks (1 L scale) or a Sartorius Stedim BIOSTAT Cplus bioreactor (10 L scale) at 37°C. Protein synthesis yields and glycosylation activity were reproducible across different batches of lysate at both small and large scale. To generate CjPglB-enriched lysate, CLM24 cells carrying plasmid pSF-CjPglB (Ollis et al., 2015) was used as the source strain. To generate FtO-PS-enriched lysates, CLM24 carrying plasmid pGAB2 (Cuccui et al., 2013) was used as the source strain. To generate one-pot lysates containing both
CjPglB and FtO-PS, EcO78-PS, or EcO7-PS, CLM24 carrying pSF-CjPglB and one of the following bacterial O-PS biosynthetic pathway plasmids was used as the source strain: pGAB2 (FtO-PS), pMW07-O78 (EcO78-PS), and pJHCV32 (EcO7-PS). CjPglB expression was induced at an OD600 of 0.8-1.0 with 0.02% (w/v) L-arabinose and cultures were moved to 30°C. Cells were grown to a final OD600 of ~3.0, at which point cells were pelleted by centrifugation at 5,000xg for 15 min at 4°C. Cell pellets were then washed three times with cold S30 buffer (10 mM Tris-acetate pH 8.2, 14 mM magnesium acetate, 60 mM potassium acetate) and pelleted at 5000xg for 10 min at 4°C. After the final wash, cells were pelleted at 7000xg for 10 min at 4°C, weighed, flash frozen in liquid nitrogen, and stored at -80°C. To make cell lysate, cell pellets were resuspended to homogeneity in 1 mL of S30 buffer per 1 g of wet cell mass. Cells were disrupted via a single passage through an Avestin EmulsiFlex-B15 (1 L scale) or EmulsiFlex-C3 (10 L scale) highpressure homogenizer at 20,000-25,000 psi. The lysate was then centrifuged twice at 30,000×g
for 30 min to remove cell debris. Supernatant was transferred to clean microcentrifuge tubes and incubated at 37°C with shaking at 250 rpm for 60 min. Following centrifugation (15,000xg) for 15 min at 4°C, supernatant was collected, aliquoted, flash-frozen in liquid nitrogen, and stored at -80°C. S30 lysate was active for about 3 freeze-thaw cycles and contained ~40 g/L total protein as measured by Bradford assay.
Cell-free protein synthesis
CFPS reactions were carried out in 1.5 mL microcentrifuge tubes (15 μL scale), 15 mL conical tubes (1 mL scale), or 50 mL conical tubes (5 mL scale) with a modified PANOx-SP system (Jewett and Swartz, 2004) . The CFPS reaction mixture consists of the following components:
1.2 mM ATP; 0.85 mM each of GTP, UTP, and CTP; 34.0 μg mL −1 L-5-formyl-5, 6, 7, 8tetrahydrofolic acid (folinic acid); 170.0 μg mL −1 of E. coli tRNA mixture; 130 mM potassium glutamate; 10 mM ammonium glutamate; 12 mM magnesium glutamate; 2 mM each of 20 amino acids; 0.4 mM nicotinamide adenine dinucleotide (NAD); 0.27 mM coenzyme-A (CoA);
1.5 mM spermidine; 1 mM putrescine; 4 mM sodium oxalate; 33 mM phosphoenolpyruvate (PEP); 57 mM HEPES; 13.3 μg mL −1 plasmid; and 27% v/v of cell lysate. For reaction volumes ³1 mL, plasmid was added at 6.67 μg mL −1 , as this lower plasmid concentration conserved reagents with no effect on protein synthesis yields or kinetics. For expression of PorA, reactions were supplemented with nanodiscs at 1 μg mL −1 , which were prepared as previously described (Schoborg et al., 2017) or purchased (Cube Biotech). For expression of CRM197 4xDQNAT , CFPS was carried out at 25°C for 20 hours, unless otherwise noted. For all other carrier proteins, CFPS was run at 30°C for 20 hours, unless otherwise noted.
For expression of TT 4xDQNAT , which contains intermolecular disulfide bonds, CFPS was carried out under oxidizing conditions. For oxidizing conditions, lysate was pre-conditioned with 750 μM iodoacetamide at room temperature for 30 min to covalently bind free sulfhydryls (-SH) and the reaction mix was supplemented with 200 mM glutathione at a 4:1 ratio of oxidized and reduced forms and 10 μM recombinant E. coli DsbC (Knapp et al., 2007) .
In vitro bioconjugate vaccine expression (iVAX)
For in vitro expression and glycosylation of carrier proteins in crude lysates, a two-phase scheme was implemented. In the first phase, CFPS was carried out for 15 min at 25-30°C as described above. In the second phase, protein glycosylation was initiated by the addition of MnCl2 and DDM at a final concentration of 25 mM and 0.1% (w/v), respectively, and allowed to proceed at 30°C for a total reaction time of 1 hour. Protein synthesis yields and glycosylation activity were reproducible across biological replicates of iVAX reactions at both small and large scale.
Reactions were then centrifuged at 20,000xg for 10 min to remove insoluble or aggregated protein products and the supernatant was analyzed by SDS-PAGE and Western blotting.
Purification of aglycosylated and glycosylated carriers from iVAX reactions was carried out using Ni-NTA agarose (Qiagen) according to manufacturer's protocols. Briefly, 0.5 mL Ni-NTA agarose per 1 mL cell-free reaction mixture was equilibrated in Buffer 1 (300 mM NaCl 50 mM NaH2PO4) with 10 mM imidazole. Soluble fractions from iVAX reactions were loaded on Ni-NTA agarose and incubated at 4°C for 2-4 hours to bind 6xHis-tagged protein. Following incubation, the cell-free reaction/agarose mixture was loaded onto a polypropylene column (BioRad) and
washed twice with 6 column volumes of Buffer 1 with 20 mM imidazole. Protein was eluted in 4 fractions, each with 0.3 mL Buffer 1 with 300 mM imidazole per mL of cell-free reaction mixture.
All buffers were used and stored at 4°C. Protein was stored at a final concentration of 1-2 mg mL -1 in sterile 1xPBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) at 4 o C.
Expression of bioconjugates in vivo using protein glycan coupling technology (PGCT)
Plasmids encoding bioconjugate carrier protein genes preceded by the DsbA leader sequence for translocation to the periplasm were transformed into CLM24 cells carrying pGAB2 and pSF-CjPglB. CLM24 carrying only pGAB2 was used as a negative control. Transformed cells were grown in 5 mL LB media (10 g L -1 yeast extract, 5 g L -1 tryptone, 5 g L -1 NaCl) overnight at 37 o C.
The next day, cells were subcultured into 100 mL LB and allowed to grow at 37 o C for 6 hours after which the culture was supplemented with 0.2% arabinose and 0.5 mM IPTG to induce expression of CjPglB and the bioconjugate carrier protein, respectively. Protein expression was then carried out for 16 hours at 30 o C, at which point cells were harvested. Cell pellets were resuspended in 1 mL sterile PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) and lysed using a Q125 Sonicator (Qsonica, Newtown, CT) at 40% amplitude in cycles of 10 sec on/10 sec off for a total of 5 min. Soluble fractions were isolated following centrifugation at 15,000 rpm for 30 min at 4 o C. Protein was purified from soluble fractions using Ni-NTA spin columns (Qiagen), following the manufacturer's protocol.
Western blot analysis
Samples were run on 4-12% Bis-Tris SDS-PAGE gels (Invitrogen). Following electrophoretic separation, proteins were transferred from gels onto Immobilon-P polyvinylidene difluoride (PVDF) membranes (0.45 μm) according to the manufacturer's protocol. Membranes were washed with PBS (80 g L -1 NaCl, 0.2 g L -1 KCl, 1.44 g L -1 Na2HPO4, 0.24 g L -1 KH2PO4, pH 7.4) followed by incubation for 1 hour in Odyssey® Blocking Buffer (LI-COR). After blocking, membranes were washed 6 times with PBST (80 g L -1 NaCl, 0.2 g L -1 KCl, 1.44 g L -1 Na2HPO4, 0.24 g L -1 KH2PO4, 1 mL L -1 Tween-20, pH 7.4) with a 5 min incubation between each wash. For iVAX samples, membranes were probed with both an anti-6xHis tag antibody and an anti-O-PS antibody or antisera specific to the O antigen of interest, if commercially available. Probing of membranes was performed for at least 1 hour with shaking at room temperature, after which membranes were washed with PBST in the same manner as described above and probed with fluorescently labeled secondary antibodies. Membranes were imaged using an Odyssey® Fc imaging system (LI-COR). CRM197 and TT production were compared to commercial DT and TT standards (Sigma) and orthogonally detected by an identical SDS-PAGE procedure followed by
Western blot analysis with a polyclonal antibody that recognizes diphtheria or tetanus toxin, respectively. All antibodies and dilutions used are listed in Table S4 .
TLR4 activation assay
HEK-Blue hTLR4 cells (Invivogen) were maintained in DMEM media, high glucose/L-glutamine supplement with 10% fetal bovine serum, 50 U mL -1 penicillin, 50 mg mL -1 streptomycin, and 100 μg mL -1 Normacin TM at 37 o C in a humidified incubator containing 5% CO2. After reaching ~50-80% confluency, cells were plated into 96-well plates at a density of 1.4 × 10 5 cells per mL in HEK-Blue detection media (Invivogen). Antigens were added at the following concentrations: 100 ng μL -1 purified protein; and 100 ng μL -1 total protein in lysate. Purified E. coli O55:B5 LPS (Sigma-Aldrich) and detoxified E. coli O55:B5 (Sigma-Aldrich) were added at 1.0 ng mL -1 and served as positive and negative controls, respectively. Plates were incubated at 37°C, 5% CO2 for 10-16 h before measuring absorbance at 620 nm. Statistical significance was determined using paired ttests.
Mouse immunization
Six groups of six-week old female BALB/c mice (Harlan Sprague Dawley) were injected subcutaneously with 100 µL PBS (pH 7.4) alone or containing purified aglycosylated MBP, FtO-PS-conjugated MBP, aglycosylated PD, or FtO-PS-conjugated PD, as previously described (Chen et al., 2010) . Groups were composed of six mice except for the PBS control group, which was composed of five mice. The amount of antigen in each preparation was normalized to 7.5 µg to ensure that an equivalent amount of aglycosylated protein or bioconjugate was administered in each case. Purified protein groups formulated in PBS were mixed with an equal volume of 
Quantification and Statistical Analysis
Quantification of cell-free protein synthesis yields
To quantify the amount of protein synthesized in iVAX reactions, two approaches were used.
Fluorescence units of sfGFP were converted to concentrations using a previously reported standard curve (Hong et al., 2014) . Yields of all other proteins were assessed via the addition of 10 μM L-14 C-leucine (11.1 GBq mmol −1 , PerkinElmer) to the CFPS mixture to yield trichloroacetic acid-precipitable radioactivity that was measured using a liquid scintillation counter as described previously (Kim and Swartz, 2001) . 
Statistical analysis
Data and Software Availability
All plasmid constructs used in this study including complete DNA sequences are deposited on Addgene (constructs 128389-128404). with FtO-PS were measured in iVAX reactions producing MBP 4xDQNAT and PD 4xDQNAT . After ~1 h, reactions produced ~40 μg mL −1 protein, as measured via 14 C-leucine incorporation, of which ~20 μg mL −1 was glycosylated with FtO-PS, as determined by densitometry. Values represent means and error bars represent standard errors of biological replicates (n = 2). To demonstrate modularity, iVAX lysates were prepared from cells expressing CjPglB and biosynthetic pathways for either (b) the E. coli O78 antigen or (c) the E. coli O7 antigen and used to synthesize PD 4xDQNAT (left) or sfGFP 217-DQNAT (right) bioconjugates. The structure and composition of the repeating monomer unit for each antigen is shown. Both polysaccharide antigens are compositionally and, in the case of the O7 antigen, structurally distinct compared to the F. tularensis O antigen. Blots show signal from probing with anti-hexa-histidine antibody (αHis) to detect the carrier protein.
Supplemental Information Titles and Legends
If a commercial anti-O-PS serum or antibody was available, it was used to confirm the identity of the conjugated O antigen (α-EcO78 blots, panel b). Asterisk denotes bands resulting from nonspecific serum antibody binding. Images are representative of at least three biological replicates.
Dashed lines indicate samples are from the same blot with the same exposure. Molecular weight ladders are shown at the left of each image. Table S1. Cost analysis for iVAX reactions, Related to STAR Methods. The total cost to assemble iVAX reactions is calculated below. A 1 mL iVAX reaction produces two 10 µg vaccine doses and can be assembled for $11.75. In the table, amino acid cost accounts for 2 mM each of the 20 canonical amino acids purchased individually from Sigma. Lysate cost is based on a single employee making 50 mL lysate from a 10 L fermentation, assuming 30 lysate batches per year and a 5-year equipment lifetime. Component source is also included in the table if it is available to purchase directly from a supplier. Homemade components cannot be purchased directly and must be prepared according to procedures described in the Methods section. Table S2 . Primers used to generate CLM24 ∆lpxM, Related to STAR Methods. Primers used to construct and verify the CLM24 ∆lpxM strain are listed below. KO primers were used for amplification of the kanamycin resistance cassette from pKD4 with homology to lpxM. Seq primers were used for colony PCRs and sequencing confirmation of knockout strains. Table S3 . Plasmids used in this study, Related to STAR Methods. Table S4 . Antibodies and antisera used in this study, Related to STAR Methods.
